“Crazy thought . Did the potus hint about Lero .
Post# of 154138
(Total Views: 758)
Posted On: 06/26/2020 9:37:04 AM
Re: reallypeople? #39280
“Crazy thought . Did the potus hint about Lero . With the statement about a big surprise.”
Based on the timing of the enrollment of the last patient in each trial (M2M mid-June and Severe late May), it seems unlikely President Trump is referring to leronlimab or leronlimab trial results. At this point in time the last patient in both trials (last patient in severe trial interim analysis) is finishing treatment. NP has stated a few times that data would be ready mid-July, which is still 2-3 weeks away. IMO, it seems unlikely the President mentioned leronlimab for these reasons.
Now, could the FDA have reached out to CYDY and asked them to analyze the data that they have now and send for review? Sure, but that seems unlikely. What seems more likely is that BP is going to push a vaccine that’s in the works and possibly a combo of remdesevir and another monoclonal antibody. Gilead has so much money and influence that they got the FDA to push remdesevir through, so I don’t doubt their power in pushing other garbage treatments forward.
Historically, I tend to be more conservative in my timelines and outlooks in regards to leronlimab’s. I’ll admit that I didn’t expect the COVID19 rum and would’ve liked to company to focus on cancer/NASH/GvHD. I hope they I’m wrong and that information regarding leronlimab and COVId has reached the FDA/government and it’ll be approved soon. The U.S. and the rest of the world need something to calm the concern that is rampant and threatening to throw the economy into a depression.
Based on the timing of the enrollment of the last patient in each trial (M2M mid-June and Severe late May), it seems unlikely President Trump is referring to leronlimab or leronlimab trial results. At this point in time the last patient in both trials (last patient in severe trial interim analysis) is finishing treatment. NP has stated a few times that data would be ready mid-July, which is still 2-3 weeks away. IMO, it seems unlikely the President mentioned leronlimab for these reasons.
Now, could the FDA have reached out to CYDY and asked them to analyze the data that they have now and send for review? Sure, but that seems unlikely. What seems more likely is that BP is going to push a vaccine that’s in the works and possibly a combo of remdesevir and another monoclonal antibody. Gilead has so much money and influence that they got the FDA to push remdesevir through, so I don’t doubt their power in pushing other garbage treatments forward.
Historically, I tend to be more conservative in my timelines and outlooks in regards to leronlimab’s. I’ll admit that I didn’t expect the COVID19 rum and would’ve liked to company to focus on cancer/NASH/GvHD. I hope they I’m wrong and that information regarding leronlimab and COVId has reached the FDA/government and it’ll be approved soon. The U.S. and the rest of the world need something to calm the concern that is rampant and threatening to throw the economy into a depression.
(1)
(0)